Furthermore, PTEN is the most frequently altered tumor suppressor gene in GBM, and its loss or mutation has been implicated in the resistance to therapies, such as tyrosine kinase inhibitors, due to permissive activation of the AKT pathway. The gene discussed is PTEN; the disease is glioblastoma.